DATE: 10/10/2001

#8

OIPE

PATENT APPLICATION: US/09/766,344 TIME: 15:09:52 Input Set : A:\PTO_VSK.txt Output Set: N:\CRF3\10102001\1766344.raw 5 <110> APPLICANT: Parkin, Neil Ziermann, Rainer 11 <120> TITLE OF INVENTION: Means And Methods For Monitoring Protease Inhibitor Antiretroviral Therapy And Guiding Therapeutic Decisions In The Treatment Of HIV/AIDS 19 <130> FILE REFERENCE: 59597 C--> 23 <140> CURRENT APPLICATION NUMBER: US/09/766,344 C--> 25 <141> CURRENT FILING DATE: 2001-09-24 29 <160> NUMBER OF SEQ ID NOS: 8 **ENTERED** 33 <170> SOFTWARE: PatentIn Ver. 2.0 37 <210> SEQ ID NO: 1 39 <211> LENGTH: 35 41 <212> TYPE: DNA 43 <213> ORGANISM: Artificial Sequence 47 <220> FEATURE: 49 <223> OTHER INFORMATION: R = A or G 53 <220> FEATURE: 55 <223> OTHER INFORMATION: Y = C or T 59 <220> FEATURE: 61 <223> OTHER INFORMATION: N = A, C, G, or T65 <220> FEATURE: 67 <223> OTHER INFORMATION: H = A, C or T71 <220> FEATURE: 73 <223> OTHER INFORMATION: Description of Artificial Sequence: 75 Oligonucleotide Primers used for PCR amplification 77 and generating site-directed mutants. 81 <400> SEQUENCE: 1 35 W--> 83 ccaattrytg tgatatttct catgntchtc ttggg 87 <210> SEQ ID NO: 2 89 <211> LENGTH: 42 91 <212> TYPE: DNA 93 <213> ORGANISM: Artificial Sequence 97 <220> FEATURE: 99 <223> OTHER INFORMATION: Description of Artificial Sequence: Oligonucleotide Primers used for PCR amplification 101 and generating site-directed mutants. 103 107 <400> SEQUENCE: 2 109 catgttgcag ggcccctagg aaaaagggct gttggaaatg tg 42 113 <210> SEQ ID NO: 3 115 <211> LENGTH: 34 117 <212> TYPE: DNA 119 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 125 <223> OTHER INFORMATION: Y = C or T 129 <220> FEATURE: 131 <223> OTHER INFORMATION: Description of Artificial Sequence:

Oligonucleotide Primers used for PCR amplification

RAW SEQUENCE LISTING

RAW SEQUENCE LISTING DATE: 10/10/2001 PATENT APPLICATION: US/09/766,344 TIME: 15:09:52

Input Set : A:\PTO_VSK.txt

Output Set: N:\CRF3\10102001\I766344.raw

```
and generating site-directed mutants.
139 <400> SEQUENCE: 3
141 cactccatgt accggttctt ttagaatytc yctg
                                                                       34
145 <210> SEQ ID NO: 4
147 <211> LENGTH: 43
149 <212> TYPE: DNA
151 <213> ORGANISM: Artificial Sequence
155 <220> FEATURE:
157 <223> OTHER INFORMATION: Description of Artificial Sequence:
         Oligonucleotide Primers used for PCR amplification
159
         and generating site-directed mutants.
161
165 <400> SEQUENCE: 4
167 actttcggac cgtccattcc tggctttaat tttactggta cag
                                                                       43
171 <210> SEQ ID NO: 5
173 <211> LENGTH: 28
175 <212> TYPE: DNA
177 <213> ORGANISM: Artificial Sequence
181 <220> FEATURE:
183 <223> OTHER INFORMATION: Description of Artificial Sequence:
         Oligonucleotide Primers used for PCR amplification
          and generating site-directed mutants.
187
191 <400> SEQUENCE: 5
193 ggggggcaat taacggaagc tctattag
                                                                       28
197 <210> SEQ ID NO: 6
199 <211> LENGTH: 30
201 <212> TYPE: DNA
203 <213> ORGANISM: Artificial Sequence
207 <220> FEATURE:
209 <223> OTHER INFORMATION: Description of Artificial Sequence:
         Oligonucleotide Primers used for PCR amplification
211
213
          and generating site-directed mutants.
217 <400> SEQUENCE: 6
219 gatggaaacc aaaattgata gggggaattg
                                                                       30
223 <210> SEQ ID NO: 7
225 <211> LENGTH: 28
227 <212> TYPE: DNA
229 <213> ORGANISM: Artificial Sequence
233 <220> FEATURE:
235 <223> OTHER INFORMATION: Description of Artificial Sequence:
         Oligonucleotide Primers used for PCR amplification
          and generating site-directed mutants.
239
243 <400> SEQUENCE: 7
                                                                       28
245 gtatgatcag atacccatag aaatctgc
249 <210> SEQ ID NO: 8
251 <211> LENGTH: 28
253 <212> TYPE: DNA
255 <213> ORGANISM: Artificial Sequence
259 <220> FEATURE:
261 <223> OTHER INFORMATION: Description of Artificial Sequence:
```

Λ

RAW SEQUENCE LISTING

.

DATE: 10/10/2001

PATENT APPLICATION: US/09/766,344

TIME: 15:09:52

Input Set : A:\PTO_VSK.txt

Output Set: N:\CRF3\10102001\1766344.raw

Oligonucleotide Primers used for PCR amplification

265 and generating site-directed mutants.

269 <400> SEQUENCE: 8

271 ctgagtcaac agacttcttc caattatg

Λ

28

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/766,344

DATE: 10/10/2001

TIME: 15:09:53

Input Set : A:\PTO_VSK.txt

Output Set: N:\CRF3\10102001\I766344.raw

L:23 M:270 C: Current Application Number differs, Replaced Current Application Number

L:25 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:83 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:1 L:83 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:1

L:83~M:341~W:~(46)~"n"~or~"Xaa"~used, for SEQ~ID#:1